Avicanna Pronounces Warrant and Debenture Repricing and Amendments
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
TORONTO, Jan. 30, 2023 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Firm”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a business stage, worldwide biopharmaceutical firm centered on the event development, and commercialization of evidence-based, cannabinoid-based merchandise, declares that the Firm has entered agreements with the holders (the “Holders”) of convertible debentures (the “Debentures”) bearing an mixture principal quantity of $1,938,000 and a maturity date of January 28, 2023 (the “Authentic Maturity Date”) and 1,056,210 widespread share buy warrants (the “Warrants”) issued pursuant to a debenture unit financing which closed on January 28, 2022 (the “Debenture Financing”), to amend the phrases of the Debentures and Warrants (the “Amending Agreements”). An mixture of $250,000 of Debentures and 136,250 Warrants (the “Insider Warrants”) had been initially issued to insiders of the Firm pursuant to the Debenture Financing.
Pursuant and topic to the phrases of the Amending Agreements, the train worth of the Warrants can be amended from $1.10 to $0.55 per widespread share of the Firm (every, a “Frequent Share”), and may have their expiry date amended from January 28, 2025, to January 28, 2026 (the “Warrant Amendments”). Debentures bearing an mixture principal quantity of $876,000 may have their conversion worth amended from $0.85 to $0.40 per Frequent Share (the “Repriced Debentures”), whereas the remaining Debentures (the “Prolonged Debentures”, and along with the Repriced Debentures, the “Amended Debentures”) bearing an mixture principal quantity of $1,062,000 may have their maturity date prolonged to July 28, 2023 (the “Debenture Amendments”). A complete of three,439,409 Frequent Shares are issuable upon conversion of the Amended Debentures. The Repriced Debentures can be transformed into an mixture of two,190,000 Frequent Shares on or earlier than the Authentic Maturity Date.
Pursuant to the coverage of the Toronto Inventory Alternate (the “TSX”) the Warrant Amendments with respect to the Insider Warrants are topic to approval of the disinterested shareholders of the Firm, which the Firm intends to hunt at its subsequent annual and particular assembly of shareholders. If disinterested shareholder approval will not be obtained, the Insider Warrants won’t be topic to the Warrant Amendments. The Warrant Amendments with respect to Holders who are usually not insiders will take impact ten (10) enterprise days following the date of this launch.
The Warrant Amendments and Debenture Amendments stay topic to the approval of TSX.
About Avicanna Inc.
Avicanna is a commercial-stage worldwide biopharmaceutical firm centered on the development and commercialization of evidence-based cannabinoid-based merchandise for the worldwide medical and pharmaceutical market segments. Avicanna has a longtime scientific platform together with R&D and scientific improvement that has led to the commercialization of greater than thirty merchandise throughout varied market segments:
Medical Hashish & Wellness Merchandise: Marketed beneath the RHO Phyto™ model these medical and wellness merchandise are a line of pharmaceutical-grade cannabinoid merchandise containing various ratios of cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio comprises a full formulary of merchandise together with oral, sublingual, topical, and transdermal deliveries which have managed dosing, enhanced absorption and stability research supported by pre-clinical information. The formulary is marketed with shopper, affected person and medical-community training and coaching.
Pharmaceutical Pipeline: Leveraging Avicanna’s scientific platform, vertical integration, and real-world proof, Avicanna has created a pipeline of patent-pending drug candidates which might be indication-specific and in varied phases of scientific improvement and commercialization. These cannabinoid-based drug candidates look to handle unmet medical wants within the areas of dermatology, persistent ache, and varied neurological issues. Avicanna’s first pharmaceutical preparation (Trunerox™) is within the drug registration stage in South America.
Click to watch Avicanna’s Corporate Video 2022
SOURCE Avicanna Inc.
For extra details about Avicanna, go to www.avicanna.com, contact Ivana Maric by e-mail at [email protected] or observe us on social media on LinkedIn, Twitter, Facebook or Instagram.
In case you are a Healthcare Skilled and want to study extra about utilizing medical hashish in your observe, please go to Avicenna Academy.
The Firm posts updates by movies from the official Firm YouTube channel.
Cautionary Be aware Concerning Ahead-Wanting Data and Statements
This information launch comprises “forward-looking info” throughout the which means of relevant securities legal guidelines. Ahead-looking info contained on this information launch could also be recognized by way of phrases akin to, “might”, “would”, “might”, “will”, “seemingly”, “anticipate”, “anticipate”, “imagine, “intend”, “plan”, “forecast”, “challenge”, “estimate”, “outlook” and different comparable expressions. Ahead-looking info contained on this information launch consists of, with out limitation, the implementation of the Warrant Amendments and Debenture Amendments, the receipt of approval of disinterested shareholders of the Firm, the receipt of all approvals of the Toronto Inventory Alternate, statements with respect to the Firm’s future enterprise operations, the opinions or beliefs of administration and future enterprise objectives. Though the Firm believes that the expectations and assumptions on which such ahead trying info relies are affordable, undue reliance shouldn’t be positioned on the forward-looking info as a result of the Firm may give no assurance that they may show to be appropriate. Precise outcomes and developments might differ materially from these contemplated by these statements. Ahead-looking info is topic to quite a lot of dangers and uncertainties that might trigger precise occasions or outcomes to vary materially from these projected within the forward-looking info. Such dangers and uncertainties embrace, however are usually not restricted to present and future market situations, together with the market worth of the widespread shares of the Firm, and the danger components set out within the Firm’s annual info kind dated March 31, 2022 and ultimate brief kind prospectus dated November 27, 2020, filed with the Canadian securities regulators and accessible beneath the Firm’s profile on SEDAR at www.sedar.com. The statements on this information launch are made as of the date of this launch. The Firm disclaims any intent or obligation to replace any forward-looking info, whether or not on account of new info, future occasions or outcomes or in any other case, apart from as required by relevant securities legal guidelines.